Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 3/2010

Open Access 01-06-2010 | Research article

Interleukin-18 as an in vivomediator of monocyte recruitment in rodent models of rheumatoid arthritis

Authors: Jeffrey H Ruth, Christy C Park, M Asif Amin, Charles Lesch, Hubert Marotte, Shiva Shahrara, Alisa E Koch

Published in: Arthritis Research & Therapy | Issue 3/2010

Login to get access

Abstract

Introduction

The function of interleukin-18 (IL-18) was investigated in pertinent animal models of rodent rheumatoid arthritis (RA) to determine its proinflammatory and monocyte recruitment properties.

Methods

We used a modified Boyden chemotaxis system to examine monocyte recruitment to recombinant human (rhu) IL-18 in vitro. Monocyte recruitment to rhuIL-18 was then tested in vivo by using an RA synovial tissue (ST) severe combined immunodeficient (SCID) mouse chimera. We defined monocyte-specific signal-transduction pathways induced by rhuIL-18 with Western blotting analysis and linked this to in vitro monocyte chemotactic activity. Finally, the ability of IL-18 to induce a cytokine cascade during acute joint inflammatory responses was examined by inducing wild-type (Wt) and IL-18 gene-knockout mice with zymosan-induced arthritis (ZIA).

Results

We found that intragraft injected rhuIL-18 was a robust monocyte recruitment factor to both human ST and regional (inguinal) murine lymph node (LN) tissue. IL-18 gene-knockout mice also showed pronounced reductions in joint inflammation during ZIA compared with Wt mice. Many proinflammatory cytokines were reduced in IL-18 gene-knockout mouse joint homogenates during ZIA, including macrophage inflammatory protein-3α (MIP-3α/CCL20), vascular endothelial cell growth factor (VEGF), and IL-17. Signal-transduction experiments revealed that IL-18 signals through p38 and ERK½ in monocytes, and that IL-18-mediated in vitro monocyte chemotaxis can be significantly inhibited by disruption of this pathway.

Conclusions

Our data suggest that IL-18 may be produced in acute inflammatory responses and support the notion that IL-18 may serve a hierarchic position for initiating joint inflammatory responses.
Appendix
Available only for authorised users
Literature
1.
Boraschi D, Dinarello CA: IL-18 in autoimmunity: review. Eur Cytokine Netwk. 2006, 17: 224-252.
2.
Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Miyawaki S, Amano T, Takeuchi T, Makino H: Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum. 2001, 44: 550-560. 10.1002/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5.CrossRefPubMed
3.
Moller B, Kukoc-Zivojnov N, Kessler U, Rehart S, Kaltwasser JP, Hoelzer D, Kalina U, Ottmann OG: Expression of interleukin-18 and its monokine-directed function in rheumatoid arthritis. Rheumatology. 2001, 40: 302-309. 10.1093/rheumatology/40.3.302.CrossRefPubMed
4.
Bresnihan B, Roux-Lombard P, Murphy E, Kane D, FitzGerald O, Dayer JM: Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis. Ann Rheum Dis. 2002, 61: 726-729. 10.1136/ard.61.8.726.PubMedCentralCrossRefPubMed
5.
Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, Kennedy K, Carter R, Wei XQ, Xu D, Field M, Foulis A, Liew FY, McInnes IB: A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest. 1999, 104: 1393-1401. 10.1172/JCI7317.PubMedCentralCrossRefPubMed
6.
Tanaka M, Harigai M, Kawaguchi Y, Ohta S, Sugiura T, Takagi K, Ohsako-Higami S, Fukasawa C, Hara M, Kamatani N: Mature form of interleukin 18 is expressed in rheumatoid arthritis synovial tissue and contributes to interferon-gamma production by synovial T cells. J Rheumatol. 2001, 28: 1779-1787.PubMed
7.
Maury CP, Tiitinen S, Laiho K, Kaarela K, Liljestrom M: Raised circulating interleukin-18 levels in reactive AA-amyloidosis. Amyloid. 2002, 9: 141-144.PubMed
8.
Scola MP, Thompson SD, Brunner HI, Tsoras MK, Witte D, Van Dijk MA, Grom AA, Passo MH, Glass DN: Interferon-gamma:interleukin 4 ratios and associated type 1 cytokine expression in juvenile rheumatoid arthritis synovial tissue. J Rheumatol. 2002, 29: 369-378.PubMed
9.
Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Morita Y, Ohmoto Y, Makino H: Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum. 2001, 44: 275-285. 10.1002/1529-0131(200102)44:2<275::AID-ANR44>3.0.CO;2-B.CrossRefPubMed
10.
Maeno N, Takei S, Imanaka H, Yamamoto K, Kuriwaki K, Kawano Y, Oda H: Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum. 2004, 50: 1935-1938. 10.1002/art.20268.CrossRefPubMed
11.
Ogata A, Kitano M, Yamanaka J, Yamasaki T, Hashimoto N, Iwasaki T, Hamano T, Fujimoto J, Kakishita E: Interleukin 18 and hepatocyte growth factor in fulminant hepatic failure of adult onset Still's disease. J Rheumatol. 2003, 30: 1093-1096.PubMed
12.
Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H: PPAR {gamma} insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004, 113: 846-855.PubMedCentralCrossRefPubMed
13.
Sawayama Y, Nabeshima S, Taniai H, Furusyo N, Kashiwagi S, Hayashi J: A Japanese case of severe refractory adult Still's disease: serum interleukin-18 is a possible marker of the response to low-dose cyclosporin A therapy. Fukuoka Igaku Zasshi. 2002, 93: 189-195.PubMed
14.
Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, Nahm DH, Park HS: Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol. 2003, 30: 2422-2427.PubMed
15.
Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M, Suwa A, Hirakata M, Mimori T: Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease: association with chronic articular disease. Rheumatology (Oxford). 2001, 40: 1398-1404. 10.1093/rheumatology/40.12.1398.CrossRef
16.
Munakata T, Uzuki M, Shimamura T, Sawai T: [Dynamics of interleukin (IL)-18 in serum, synovial fluid and synovial membrane in the patients with rheumatoid arthritis]. Ryumachi. 2001, 41: 625-634.PubMed
17.
Joosten LA, Radstake TR, Lubberts E, van den Bersselaar LA, van Riel PL, van Lent PL, Barrera P, van den Berg WB: Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum. 2003, 48: 339-347. 10.1002/art.10814.CrossRefPubMed
18.
Mosaad YM, Metwally SS, Auf FA, Abd ELSER, el-Deek B, Limon NI, el-Chennawi FA: Proinflammatory cytokines (IL-12 and IL-18) in immune rheumatic diseases: relation with disease activity and autoantibodies production. Egypt J Immunol. 2003, 10: 19-26.PubMed
19.
Eriksson P, Andersson C, Ekerfelt C, Ernerudh J, Skogh T: Sjogren's syndrome with myalgia is associated with subnormal secretion of cytokines by peripheral blood mononuclear cells. J Rheumatol. 2004, 31: 729-735.PubMed
20.
Chen DY, Lan JL, Lin FJ, Hsieh TY: Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol. 2004, 31: 2189-2198.PubMed
21.
Rooney T, Murphy E, Benito M, Roux-Lombard P, FitzGerald O, Dayer JM, Bresnihan B: Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis. 2004, 63: 1393-1398. 10.1136/ard.2003.016428.PubMedCentralCrossRefPubMed
22.
Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC: Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease. Ann Rheum Dis. 2004, 63: 1300-1306. 10.1136/ard.2003.013680.PubMedCentralCrossRefPubMed
23.
Okamura H, Kashiwamura S, Ueda H: [Interleukin-18 in pathogenesis of rheumatoid arthritis]. Nippon Rinsho. 2005, 63 (suppl 1): 175-180.PubMed
24.
Miranda LA, Fischer RG, Sztajnbok FR, Johansson A, Figueredo CM, Gustafsson A: Increased interleukin-18 in patients with juvenile idiopathic arthritis and early attachment loss. J Periodontol. 2005, 76: 75-82. 10.1902/jop.2005.76.1.75.CrossRefPubMed
25.
Chen DY, Lan JL, Lin FJ, Hsieh TY: Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still's disease. Arthritis Rheum. 2005, 53: 320-327. 10.1002/art.21164.CrossRefPubMed
26.
Arlet JB, Le Thi Huong DB, Pouchot J, Piette JC: [Current concepts on the physiopathology of adult-onset Still's disease]. Rev Méd Interne. 2005, 26: 549-556. 10.1016/j.revmed.2004.11.021.CrossRefPubMed
27.
van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP: Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006, 65: 1551-1557. 10.1136/ard.2005.050963.PubMedCentralCrossRefPubMed
28.
Chensue SW, Warmington K, Ruth JH, Lukacs N, Kunkel SL: Mycobacterial and schistosomal antigen-elicited granuloma formation in IFN-gamma and IL-4 knockout mice: analysis of local and regional cytokine and chemokine networks. J Immunol. 1997, 159: 3565-3573.PubMed
29.
Ruth JH, Bienkowski M, Warmington KS, Lincoln PM, Kunkel SL, Chensue SW: IL-1 receptor antagonist (IL-1ra) expression, function, and cytokine-mediated regulation during mycobacterial and schistosomal antigen-elicited granuloma formation. J Immunol. 1996, 156: 2503-2509.PubMed
30.
Hessian PA, Highton J, Kean A, Sun CK, Chin M: Cytokine profile of the rheumatoid nodule suggests that it is a Th1 granuloma. Arthritis Rheum. 2003, 48: 334-338. 10.1002/art.10776.CrossRefPubMed
31.
Morel JC, Park CC, Zhu K, Kumar P, Ruth JH, Koch AE: Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J Biol Chem. 2002, 277: 34679-34691. 10.1074/jbc.M206337200.CrossRefPubMed
32.
McInnes IB, Gracie JA, Liew FY: Interleukin-18: a novel cytokine in inflammatory rheumatic disease. Arthritis Rheum. 2001, 44: 1481-1483. 10.1002/1529-0131(200107)44:7<1481::AID-ART268>3.0.CO;2-1.CrossRefPubMed
33.
Morel JC, Park CC, Kumar P, Koch AE: Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NFkappaB activation. Lab Invest. 2001, 81: 1371-1383.CrossRefPubMed
34.
Ruth JH, Volin MV, Haines GK, Woodruff DC, Katschke KJ, Woods JM, Park CC, Morel JC, Koch AE: Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum. 2001, 44: 1568-1581. 10.1002/1529-0131(200107)44:7<1568::AID-ART280>3.0.CO;2-1.CrossRefPubMed
35.
Ruth JH, Shahrara S, Park CC, Morel JC, Kumar P, Qin S, Koch AE: Role of macrophage inflammatory protein-3alpha and its ligand CCR6 in rheumatoid arthritis. Lab Invest. 2003, 83: 579-588.CrossRefPubMed
36.
Kontzias A, Efthimiou P: Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances. Drugs. 2008, 68: 319-337. 10.2165/00003495-200868030-00005.CrossRefPubMed
37.
Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE: Evidence of IL-18 as a novel angiogenic mediator. J Immunol. 2001, 167: 1644-1653.CrossRefPubMed
38.
Morel JC, Park CC, Woods JM, Koch AE: A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem. 2001, 276: 37069-37075. 10.1074/jbc.M103574200.CrossRefPubMed
39.
Kohno K, Kurimoto M: Interleukin 18, a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both. Clin Immunol Immunopathol. 1998, 86: 11-15. 10.1006/clin.1997.4475.CrossRefPubMed
40.
Olee T, Hashimoto S, Quach J, Lotz M: IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J Immunol. 1999, 162: 1096-1100.PubMed
41.
Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, Okamura H, Kurimoto M, Chambers TJ, Martin TJ, Gillespie MT: Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med. 1997, 185: 1005-1012. 10.1084/jem.185.6.1005.PubMedCentralCrossRefPubMed
42.
Naik SM, Cannon G, Burbach GJ, Singh SR, Swerlick RA, Wilcox JN, Ansel JC, Caughman SW: Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with pro-inflammatory mediators and dinitrochlorobenzene. J Invest Dermatol. 1999, 113: 766-772. 10.1046/j.1523-1747.1999.00750.x.CrossRefPubMed
43.
Stoll S, Muller G, Kurimoto M, Saloga J, Tanimoto T, Yamauchi H, Okamura H, Knop J, Enk AH: Production of IL-18 (IFN-gamma-inducing factor) messenger RNA and functional protein by murine keratinocytes. J Immunol. 1997, 159: 298-302.PubMed
44.
Stoll S, Jonuleit H, Schmitt E, Muller G, Yamauchi H, Kurimoto M, Knop J, Enk AH: Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol. 1998, 28: 3231-3239. 10.1002/(SICI)1521-4141(199810)28:10<3231::AID-IMMU3231>3.0.CO;2-Q.CrossRefPubMed
45.
Marotte H, Ahmed S, Ruth JH, Koch AE: Blocking ERK-½ reduces tumor necrosis factor alpha-induced interleukin-18 bioactivity in rheumatoid arthritis synovial fibroblasts by induction of interleukin-18 binding protein A. Arthritis Rheum. 2010, 62: 722-731. 10.1002/art.27269.PubMedCentralCrossRefPubMed
46.
Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K: Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol. 1998, 70: 281-312. full_text.CrossRefPubMed
47.
Matsumoto S, Tsuji-Takayama K, Aizawa Y, Koide K, Takeuchi M, Ohta T, Kurimoto M: Interleukin-18 activates NF-kappaB in murine T helper type 1 cells. Biochem Biophys Res Commun. 1997, 234: 454-457. 10.1006/bbrc.1997.6665.CrossRefPubMed
48.
Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA, Hayashi N, Higashino K, Okamura H, Nakanishi K, Kurimoto M, Tanimoto T, Flavell RA, Sato V, Harding MW, Livingston DJ, Su MS: Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science. 1997, 275: 206-209. 10.1126/science.275.5297.206.CrossRefPubMed
49.
Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A, Quintal L, Sekut L, Talanian R, Paskind M, Wong W, Kamen R, Tracey D, Allen H: Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature. 1997, 386: 619-623. 10.1038/386619a0.CrossRefPubMed
50.
Wei XQ, Leung BP, Arthur HM, McInnes IB, Liew FY: Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol. 2001, 166: 517-521.CrossRefPubMed
51.
Smeets RL, van de Loo FA, Arntz OJ, Bennink MB, Joosten LA, van den Berg WB: Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther. 2003, 10: 1004-1011. 10.1038/sj.gt.3301986.CrossRefPubMed
52.
Banda NK, Vondracek A, Kraus D, Dinarello CA, Kim SH, Bendele A, Senaldi G, Arend WP: Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J Immunol. 2003, 170: 2100-2105.CrossRefPubMed
53.
Plater-Zyberk C, Joosten LA, Helsen MM, Sattonnet-Roche P, Siegfried C, Alouani S, van De Loo FA, Graber P, Aloni S, Cirillo R, Lubberts E, Dinarello CA, van Den Berg WB, Chvatchko Y: Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest. 2001, 108: 1825-1132.PubMedCentralCrossRefPubMed
54.
Joosten LA, van De Loo FA, Lubberts E, Helsen MM, Netea MG, van Der Meer JW, Dinarello CA, van Den Berg WB: An IFN-gamma-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. J Immunol. 2000, 165: 6553-6558.CrossRefPubMed
55.
Shi FD, Wang HB, Li H, Hong S, Taniguchi M, Link H, Van Kaer L, Ljunggren HG: Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol. 2000, 1: 245-251. 10.1038/79792.CrossRefPubMed
56.
Kumar P, Hosaka S, Koch AE: Soluble E-selectin induces monocyte chemotaxis through Src family tyrosine kinases. J Biol Chem. 2001, 276: 21039-21045. 10.1074/jbc.M009099200.CrossRefPubMed
57.
Robinson CJ, Scott PH, Allan AB, Jess T, Gould GW, Plevin R: Treatment of vascular smooth muscle cells with antisense phosphorothioate oligodeoxynucleotides directed against p42 and p44 mitogen-activated protein kinases abolishes DNA synthesis in response to platelet-derived growth factor. Biochem J. 1996, 320: 123-127.PubMedCentralCrossRefPubMed
58.
Hreniuk D, Garay M, Gaarde W, Monia BP, McKay RA, Cioffi CL: Inhibition of c-Jun N-terminal kinase 1, but not c-Jun N-terminal kinase 2, suppresses apoptosis induced by ischemia/reoxygenation in rat cardiac myocytes. Mol Pharmacol. 2001, 59: 867-874.PubMed
59.
Zhu K, Amin MA, Zha Y, Harlow LA, Koch AE: Mechanism by which H-2g, a glucose analog of blood group H antigen, mediates angiogenesis. Blood. 2005, 105: 2343-2349. 10.1182/blood-2004-08-3140.CrossRefPubMed
60.
Duan W, Chan JH, McKay K, Crosby JR, Choo HH, Leung BP, Karras JG, Wong WS: Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med. 2005, 171: 571-578. 10.1164/rccm.200408-1006OC.CrossRefPubMed
61.
Ruth JH, Haas CS, Park CC, Amin MA, Martinez RJ, Haines GK, Shahrara S, Campbell PL, Koch AE: CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum. 2006, 54: 765-778. 10.1002/art.21662.PubMedCentralCrossRefPubMed
62.
Woods JM, Katschke KJ, Volin MV, Ruth JH, Woodruff DC, Amin MA, Connors MA, Kurata H, Arai K, Haines GK, Kumar P, Koch AE: IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J Immunol. 2001, 166: 1214-1222.CrossRefPubMed
63.
Puren AJ, Fantuzzi G, Gu Y, Su MS, Dinarello CA: Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest. 1998, 101: 711-721. 10.1172/JCI1379.PubMedCentralCrossRefPubMed
64.
Thomassen E, Bird TA, Renshaw BR, Kennedy MK, Sims JE: Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1Rrp1 leads to activation of signaling pathways similar to those used by interleukin-1. J Interferon Cytokine Res. 1998, 18: 1077-1088. 10.1089/jir.1998.18.1077.CrossRefPubMed
65.
Lee JK, Kim SH, Lewis EC, Azam T, Reznikov LL, Dinarello CA: Differences in signaling pathways by IL-1beta and IL-18. Proc Natl Acad Sci USA. 2004, 101: 8815-8820. 10.1073/pnas.0402800101.PubMedCentralCrossRefPubMed
66.
Komai-Koma M, Gracie JA, Wei XQ, Xu D, Thomson N, McInnes IB, Liew FY: Chemoattraction of human T cells by IL-18. J Immunol. 2003, 170: 1084-1090.CrossRefPubMed
67.
Gutzmer R, Langer K, Mommert S, Wittmann M, Kapp A, Werfel T: Human dendritic cells express the IL-18R and are chemoattracted to IL-18. J Immunol. 2003, 171: 6363-6371.CrossRefPubMed
68.
Kannan K, Ortmann RA, Kimpel D: Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology. 2005, 12: 167-181. 10.1016/j.pathophys.2005.07.011.CrossRefPubMed
69.
Leung BP, McInnes IB, Esfandiari E, Wei XQ, Liew FY: Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. J Immunol. 2000, 164: 6495-6502.CrossRefPubMed
70.
Canetti CA, Leung BP, Culshaw S, McInnes IB, Cunha FQ, Liew FY: IL-18 enhances collagen-induced arthritis by recruiting neutrophils via TNF-alpha and leukotriene B4. J Immunol. 2003, 171: 1009-1015.CrossRefPubMed
71.
Keystone EC, Schorlemmer HU, Pope C, Allison AC: Zymosan-induced arthritis: a model of chronic proliferative arthritis following activation of the alternative pathway of complement. Arthritis Rheum. 1977, 20: 1396-1401. 10.1002/art.1780200714.CrossRefPubMed
72.
Frasnelli ME, Tarussio D, Chobaz-Peclat V, Busso N, So A: TLR2 modulates inflammation in zymosan-induced arthritis in mice. Arthritis Res Ther. 2005, 7: R370-R379. 10.1186/ar1494.PubMedCentralCrossRefPubMed
73.
Di Carlo FJ, Fiore JV: On the composition of zymosan. Science. 1958, 127: 756-757. 10.1126/science.127.3301.756-a.CrossRefPubMed
74.
Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M, Aderem A: The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature. 1999, 401: 811-815. 10.1038/44605.CrossRefPubMed
75.
Fearon DT, Austen KF: Activation of the alternative complement pathway due to resistance of zymosan-bound. Proc Natl Acad Sci USA. 1977, 74: 1683-1687. 10.1073/pnas.74.4.1683.PubMedCentralCrossRefPubMed
76.
77.
Schorlemmer HU, Bitter-Suermann D, Allison AC: Complement activation by the alternative pathway and macrophage enzyme secretion in the pathogenesis of chronic inflammation. Immunology. 1977, 32: 929-940.PubMedCentralPubMed
78.
Ruth JH, Amin MA, Woods JM, He X, Samuel S, Yi N, Haas CS, Koch AE, Bullard DC: Accelerated development of arthritis in mice lacking endothelial selectins. Arthritis Res Ther. 2005, 7: R959-R970. 10.1186/ar1770.PubMedCentralCrossRefPubMed
79.
Liu H, Rohowsky-Kochan C: Regulation of IL-17 in human CCR6+ effector memory T cells. J Immunol. 2008, 180: 7948-7957.CrossRefPubMed
80.
Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, Feldmann M, Maini RN: Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999, 163: 1521-1528.PubMed
Metadata
Title
Interleukin-18 as an in vivomediator of monocyte recruitment in rodent models of rheumatoid arthritis
Authors
Jeffrey H Ruth
Christy C Park
M Asif Amin
Charles Lesch
Hubert Marotte
Shiva Shahrara
Alisa E Koch
Publication date
01-06-2010
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2010
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3055

Other articles of this Issue 3/2010

Arthritis Research & Therapy 3/2010 Go to the issue

Research article

Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial

Editorial

Angiotensin-converting enzyme 2 autoantibodies: further evidence for a role of the renin-angiotensin system in inflammation

Research article

Association of IL4Rsingle-nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis

Letter

Functional significance of nerve growth factor and its receptor (TrkA) in inflammatory arthritis

Research article

Provision of preventive health care in systemic lupus erythematosus: data from a large observational cohort study

Research article

Physiological tonicity improves human chondrogenic marker expression through nuclear factor of activated T-cells 5 in vitro
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits